Veeva Systems vs State Street SPDR S&P Biotech ETF — how do they compare? Veeva Systems trades at $296.13 (market cap $46.12B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Veeva Systems is far larger — about 4.6× State Street SPDR S&P Biotech ETF's market cap, and Veeva Systems is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Veeva Systems for 6 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VEEV | XBI | |
|---|---|---|
Market Cap | $46.12B | $10.11B |
Volume | 921,537 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $299.10 | $169.55 |
52-Week Low | $151.43 | $104.99 |
Typical Hold Time | 6 Days | 38 Days |
Enterprise Value | $39.03B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →